Video

View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Published: 10 Mar 2023

  • Views:

    Views Icon 672
  • Likes:

    Heart Icon 2
Average (ratings)
No ratings
Your rating

Prof Nicolas Van Mieghem and Dr Joost Daemen interprets the findings from the top 10 ACC.23/WCC late-breaking and featured science trials and studies in their critical View from the Thoraxcenter review series. Join them as they consider the implications for research and offer an insight into how they will incorporate the latest data into their day-to-day clinical practice. 

What are the top trials of ACC.23/WCC? What are the considerations for practice? What is next?

Trials covered in detail include:


Structural Intervention
00:25: TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation
04:24: UK Mini Mitral: Minimally Invasive Versus Conventional Sternotomy for Mitral Valve Repair Surgery: An Expertise Based Multicentre Randomised Controlled Trial
06:04: COAPT: Transcatheter Edge-to-edge Repair of Functional Mitral Regurgitation in Heart Failure: Final Five-year Results
10:15: Evolut Low Risk: Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 3-year Outcomes

Coronary Intervention  
11:46: REVIVED-BCIS2: Effect of Myocardial Viability, Percutaneous Coronary Intervention and Functional Recovery on Clinical Outcomes
14:10: RENOVATE-COMPLEX-PCI: Intravascular Imaging-guided Versus Angiography-guided Procedural Optimization in Complex Percutaneous Coronary Intervention
17:53: BIOVASC: Complete Revascularization Strategies in Patients Presenting with Acute Coronary Syndromes and Multivessel Coronary Disease

Statins
23:53: Yellow III: Effect Of Evolocumab On Coronary Plaque Characteristics in Stable Coronary Artery Disease: A Multimodality Imaging Study 
26:40: CLEAR Outcomes: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients At High Cardiovascular Risk
31:18: MK-0616: Efficacy And Safety of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, in the Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Get a critical review of the ACC.23/WCC late-breaking and featured data!

For more content from ACC.23/WCC and the Late-breaker Discussion series head to Late-Breaking Science Video Collection.

 

Comments

You must be to comment. If you are not registered, you can register here.